Martin Vogelbaum is currently a Partner at Rho Ventures. He has more than 24 years of private and public deal transaction and investment experience in the life sciences as both a senior business development executive and venture capitalist. Mr. Vogelbaum joined Rho as a Partner in 2005 and primarily focuses on investments in biotechnology. Some representative investments include Cara (CARA), Gloucester Pharmaceuticals (sold to Celgene), SARcode Biosciences (sold to Shire), AqueSys (sold to Allergan) and Mersana Therapeutics (MRSN). From 2015-2017, Mr. Vogelbaum served as a Corporate Vice President, Business Development at Celgene Corporation (CELG) where he completed over $1.5B in product licensing and M&A transactions with private and public companies. Prior to Rho, he was a General Partner at Apple Tree Partners, a life sciences venture firm focused on early-stage companies and a General Partner at Oxford Bioscience Partners. Mr. Vogelbaum was a research associate in the bone marrow transplantation unit at Memorial-Sloan Kettering Hospital, where he conducted research in graft-versus-host-disease (GVHD). He received an A.B. in biology and history from Columbia University. He currently serves on the Healthcare Advisory Board for the Partnership Fund for New York City as well as the Scientific Advisory Committee for Weill Cornell Medical College’s Daedalus Fund for Innovation.